These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37640175)

  • 1. Use of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation.
    Jafri SH; Hushcha P; Dorbala P; Bousquet G; Lutfy C; Mellett L; Sonis L; Blankstein R; Cannon C; Plutzky J; Polk D; Skali H
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt A):102058. PubMed ID: 37640175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
    Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
    Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous coronary intervention vs. optimal medical therapy--the other side of the coin: medication adherence.
    Kocas C; Abaci O; Oktay V; Coskun U; Bostan C; Yildiz A; Arat Ozkan A; Gurmen T; Ersanli M
    J Clin Pharm Ther; 2013 Dec; 38(6):476-9. PubMed ID: 23992279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-Converting Enzyme Inhibitor-based Versus Angiotensin Receptor Blocker-based Optimal Medical Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.
    Park S; Kim YG; Ann SH; Park HW; Suh J; Roh JH; Cho YR; Han S; Park GM
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):61-68. PubMed ID: 33165139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario.
    Garg P; Wijeysundera HC; Yun L; Cantor WJ; Ko DT
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25122664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
    Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
    Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Medication Use in Patients with Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease.
    Adatia F; Galway S; Grubisic M; Lee M; Daniele P; Humphries KH; Sedlak TL
    J Womens Health (Larchmt); 2017 Nov; 26(11):1185-1192. PubMed ID: 28384014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Optimal Medical Therapy Before Procedures on Outcomes in Coronary Patients Treated With Drug-Eluting Stents.
    Iijima R; Nakamura M; Matsuyama Y; Muramatsu T; Yokoi H; Hara H; Okada H; Ochiai M; Suwa S; Hozawa H; Kawai K; Awata M; Mukawa H; Fujita H; Nanto S;
    Am J Cardiol; 2016 Sep; 118(6):790-796. PubMed ID: 27544742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
    Mentz RJ; Allen BD; Kwasny MJ; Konstam MA; Udelson JE; Ambrosy AP; Fought AJ; Vaduganathan M; O'Connor CM; Zannad F; Maggioni AP; Swedberg K; Bonow RO; Gheorghiade M
    Eur J Heart Fail; 2013 Jan; 15(1):61-8. PubMed ID: 22968743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy.
    Soldati S; Di Martino M; Rosa AC; Fusco D; Davoli M; Mureddu GF
    BMC Cardiovasc Disord; 2021 Sep; 21(1):466. PubMed ID: 34565326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
    Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
    Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex Differences in Cardiac Medication Use Post-Catheterization in Patients Undergoing Coronary Angiography for Stable Angina with Nonobstructive Coronary Artery Disease.
    Galway S; Adatia F; Grubisic M; Lee M; Daniele P; Humphries KH; Sedlak TL
    J Womens Health (Larchmt); 2017 Sep; 26(9):976-983. PubMed ID: 28384013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020.
    Ødegaard KM; Lirhus SS; Melberg HO; Hallén J; Halvorsen S
    ESC Heart Fail; 2023 Feb; 10(1):405-415. PubMed ID: 36266969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of Insufficient Optimal Medical Therapy after Acute Myocardial Infarction.
    Haraguchi Y; Sakakura K; Yamamoto K; Taniguchi Y; Tsukui T; Seguchi M; Wada H; Momomura SI; Fujita H
    Intern Med; 2020 Jun; 59(12):1489-1495. PubMed ID: 32188806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization.
    Kawashima H; Serruys PW; Ono M; Hara H; O'Leary N; Mack MJ; Holmes DR; Morice MC; Head SJ; Kappetein AP; Thuijs DJFM; Milojevic M; Noack T; Mohr FW; Davierwala PM; Sharif F; McEvoy JW; Onuma Y;
    J Am Coll Cardiol; 2021 Jul; 78(1):27-38. PubMed ID: 34210411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
    Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
    Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.